Compare NCMI & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | QTRX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 352.7M |
| IPO Year | 2007 | 2017 |
| Metric | NCMI | QTRX |
|---|---|---|
| Price | $3.87 | $6.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | $6.88 | ★ $10.33 |
| AVG Volume (30 Days) | 414.2K | ★ 804.7K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,300,000.00 | $130,203,000.00 |
| Revenue This Year | $3.66 | N/A |
| Revenue Next Year | $12.17 | $28.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.81 | $4.05 |
| 52 Week High | $7.25 | $12.41 |
| Indicator | NCMI | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 44.17 |
| Support Level | $3.98 | $7.44 |
| Resistance Level | $4.12 | $7.55 |
| Average True Range (ATR) | 0.14 | 0.41 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 1.09 | 4.38 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.